Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FGFR2::CASP7 status confers therapeutic sensitivity to Erdafitinib in patients with Bladder Urothelial Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.